4:20 PM
 | 
Oct 05, 2018
 |  BioCentury  |  Finance

Fruitful partnerships

VelosBio marks the first start-up to emerge from Arix’s partnerships

Arix Bioscience plc (LSE:ARIX) leveraged its partnership with Takeda Ventures to co-lead a $58 million series A round for antibody-drug company VelosBio Inc., a sign that the VC’s strategic partnerships are finally bearing fruit.

Also participating in the round, which closed Oct. 1., were co-lead investor Sofinnova Ventures, new investors Pappas Ventures and Chiesi Ventures and fellow existing investor Decheng Capital.

Arix launched in 2016 and raised £100 million ($130.5 million) in an IPO on...

Read the full 351 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >